

Rise in Gene Therapy Driving Growth: Key Driver Transforming Familial Mediterranean Fever Pharmaceuticals Market 2025

The Business Research Company's Gene Therapy Global Market Report 2025 - Market Size, Trends, And Global Forecast 2025-2034

LONDON, GREATER LONDON, UNITED KINGDOM, May 27, 2025
/EINPresswire.com/ -- The Business Research Company's Latest Report Explores Market Driver, Trends, Regional Insights - Market Sizing & Forecasts Through 2034.

The Business
Research Company

Gene Therapy Market Report 2025 - Market Size, Trends, And Global Forecast 2025-2034

How Significant Is The Familial Mediterranean Fever Pharmaceuticals Market?

“

The Business Research Company's Latest Report Explores Market Driver, Trends, Regional Insights - Market Sizing & Forecasts Through 2034.

”

*The Business Research
Company*

The familial mediterranean fever pharmaceuticals market is poised for significant growth. From \$1.64 billion in 2024, it is projected to reach \$1.74 billion in 2025, reflecting a healthy compound annual growth rate of 5.9%. This surge over the historic period can be attributed to increased disease prevalence, migration, and geriatric population, along with a rise in genetic alterations within the MEFV gene and genetic mutation.

What Is The Projected Market Size And Growth Rate For The Familial Mediterranean Fever Pharmaceuticals Market?

[Growth of the Familial Mediterranean Fever Pharmaceuticals market](#) is projected to continue, reaching \$2.15 billion in 2029 at a CAGR of 5.5%. This forecasted growth can be connected to various factors including the increasing adoption of advanced cancer therapeutics, growing interest in gene therapy and biologics, rise in application of advanced therapy, heightened usage of effective medications, and widespread adoption of supportive therapies. Emerging trends in

the forecast period include advancements in treatment, introduction of new drug classes, collaborations between academic institutions, research organizations, and pharmaceutical companies, adaptation of new therapeutics, and advances in technology.

Get Your Free Sample Market Report:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=23397&type=smp>

What Key Factors Are Driving The Growth Of The Familial Mediterranean Fever Pharmaceuticals Market?

Moving forward, gene therapy is expected to drive the growth of the familial Mediterranean Fever FMF pharmaceuticals market. It is a medical approach that amends or replaces faulty genes to prevent or treat diseases at the genetic level. The increasing potential of gene therapy is due to advancements in genetic engineering that allow for precise targeting and correction of genetic disorders, providing potential cures for diseases previously considered untreatable. By targeting the root cause mutations in the MEFV gene, gene therapy offers the possibility of a long-term or even permanent cure for FMF rather than simple symptom management.

Order Your Report Now For A Swift Delivery:

<https://www.thebusinessresearchcompany.com/report/familial-mediterranean-fever-pharmaceuticals-global-market-report>

Who Are The Key Industry Players In The Familial Mediterranean Fever Pharmaceuticals Market?

Key players in the FMF pharmaceuticals market include Merck & Co. Inc., Bristol Myers Squibb, Novartis International AG, Takeda Pharmaceutical Company Limited, Amgen Inc., Swedish Orphan Biovitrum AB Sobi, Granules Pharmaceuticals Inc., Sanmar Group, Indena S.p.A., Harman Finocem, Camber Pharmaceuticals Inc., R-Pharm Group, Alchem International, AdvaCare Pharma USA LLC, ViennaLab Diagnostics GmbH, Honour Lab Ltd., Vital Laboratories Pvt. Ltd., Enomark Biotech Pvt. Ltd., Gonane Pharma, and Ennature Biopharma.

These market leaders are developing advanced treatments such as cost-effective generic alternatives, and exploring novel biologics and gene therapies, a trend that continues to shape the market. These generic alternatives are lower-cost versions of brand-name drugs that retain the same active ingredients, dosage, safety, and efficacy.

The people affected by FMF can benefit from various drug types, routes of administration, and end users.

How Is The Familial Mediterranean Fever Pharmaceuticals Market Segmented?

The market is segmented as follows:

- 1 Drug Type: Colchicine, Interleukin-1 Inhibitors, Anti-IL-6 Drugs
- 2 Route Of Administration: Oral, Injectable
- 3 End Users: Hospitals, Clinical Diagnostic Laboratories, Other End Users

Additionally, the market's subsegments include:

- 1 By Colchicine: Oral Colchicine, Intravenous Colchicine
- 2 By Interleukin-1 Inhibitors: Anakinra, Canakinumab, Rilonacept
- 3 By Anti-IL-6 Drugs: Tocilizumab, Sarilumab, Siltuximab

What Are The Regional Insights Into The Familial Mediterranean Fever Pharmaceuticals Market? In 2024, the Middle East was the largest region in the FMF pharmaceuticals market while the Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Browse Through More Similar Reports By The Business Research Company:

Generic Pharmaceuticals Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/generic-pharmaceuticals-global-market-report>

Veterinary Pharmaceuticals Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/veterinary-pharmaceuticals-global-market-report>

Mid-Size Pharmaceuticals Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/mid-size-pharmaceuticals-global-market-report>

About The Business Research Company

Learn more about us. The Business Research Company has over 15000+ reports from 27 industries covering 60+ geographies and has built a reputation for offering comprehensive, data-rich research and insights. With 1,500,000 datasets and the optimistic contribution of in-depth secondary research, coupled with unique insights from industry leaders, we provide the information you need to stay ahead of the game.

Contact us at:

The Business Research Company: <https://www.thebusinessresearchcompany.com/>

Americas: +1 3156230293

Asia: +44 2071930708

Europe: +44 2071930708

Email us at info@tbrc.info

Follow us on LinkedIn: <https://in.linkedin.com/company/the-business-research-company> and YouTube: https://www.youtube.com/channel/UC24_f10rV8cR5DxICpgmyFQ or get an overview of the global market model: <https://www.thebusinessresearchcompany.com/global-market-model>.

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[LinkedIn](#)

[Facebook](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/816377079>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.